These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22795293)

  • 41. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
    J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy.
    Attia FM; Hassan AM; El-Maraghy NN; Ibrahium GH
    Cancer Biomark; 2011-2012; 11(1):41-7. PubMed ID: 22820139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.
    Shah MS; Fogelman DR; Raghav KP; Heymach JV; Tran HT; Jiang ZQ; Kopetz S; Daniel CR
    Cancer; 2015 Sep; 121(17):2968-75. PubMed ID: 25975416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of some inflammatory markers in patients with lymphoma.
    Hamed Anber N; El-Sebaie AH; Darwish NHE; Mousa SA; Shamaa SS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30814315
    [No Abstract]   [Full Text] [Related]  

  • 45. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort.
    Conroy SM; Maskarinec G; Morimoto Y; Franke AA; Cooney RV; Wilkens LR; Goodman MT; Hernadez BY; Le Marchand L; Henderson BE; Kolonel LN
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):337-47. PubMed ID: 23300021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteinuria is a simple sign of systemic inflammation that leads to a poor prognosis in individuals affected with non-Hodgkin lymphoma.
    Hara M; Ando M; Maeda Y; Tsuchiya K; Nitta K
    Clin Nephrol; 2014 Jul; 82(1):51-7. PubMed ID: 24887301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects.
    da Silva PB; Perini GF; Pereira Lde A; Sacconato EM; Penna AM; Garibaldi J; Cavalcante E; Baiocchi OC
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S151-7. PubMed ID: 26297269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.
    Tedeschi R; Bidoli E; Bortolin MT; Schioppa O; Vaccher E; De Paoli P
    Oncotarget; 2015 Oct; 6(30):30334-42. PubMed ID: 26296972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
    Marri PR; Hodge LS; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Cerhan JR; Novak AJ; Ansell SM
    Clin Cancer Res; 2013 Dec; 19(24):6812-9. PubMed ID: 24141626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.
    Purdue MP; Lan Q; Bagni R; Hocking WG; Baris D; Reding DJ; Rothman N
    Cancer Res; 2011 Jul; 71(14):4898-907. PubMed ID: 21632552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.
    Vendrame E; Hussain SK; Breen EC; Magpantay LI; Widney DP; Jacobson LP; Variakojis D; Knowlton ER; Bream JH; Ambinder RF; Detels R; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):343-9. PubMed ID: 24220912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
    Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients.
    Chen ZY; He WZ; Peng LX; Jia WH; Guo RP; Xia LP; Qian CN
    Int J Cancer; 2015 Feb; 136(3):584-92. PubMed ID: 24916890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.
    Fayad L; Cabanillas F; Talpaz M; McLaughlin P; Kurzrock R
    Leuk Lymphoma; 1998 Aug; 30(5-6):563-71. PubMed ID: 9711918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis.
    Fahmi MN; Pradjatmo H; Astuti I; Nindrea RD
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):315-323. PubMed ID: 33639643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased Cytokine Levels Assist in the Diagnosis of Respiratory Bacterial Infections or Concurrent Bacteremia in Patients With Non-Hodgkin's Lymphoma.
    Zhang L; Zhang J; He H; Ling X; Li F; Yang Z; Zhao J; Li H; Yang T; Zhao S; Shi K; Guan X; Zhao R; Li Z
    Front Cell Infect Microbiol; 2022; 12():860526. PubMed ID: 35463642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
    Etto L; Lacerda E; Baiocchi O; Silva V; Dalboni M; Alves A; Silva M; Vettore A; Colleoni G
    Leuk Lymphoma; 2008 Feb; 49(2):257-64. PubMed ID: 18231911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study.
    Kathpalia M; Mishra P; Majid A; Khan MA; Sharma A; Bhurani D; Nidhi
    J Neuroimmunol; 2024 Jul; 392():578372. PubMed ID: 38788317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
    Khalifa KA; Alkilani AA; Ismail H; Soliman MA
    J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.
    Aschebrook-Kilfoy B; Zheng T; Foss F; Ma S; Han X; Lan Q; Holford T; Chen Y; Leaderer B; Rothman N; Zhang Y
    J Cancer Surviv; 2012 Mar; 6(1):102-14. PubMed ID: 22113576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.